Mundipharma and CorMedix have unveiled a win for their antifungal drug Rezzayo at preventing invasive fungal diseases in ...

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in HSCT patients.

Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in ...

Mundipharma and CorMedix announced that their antifungal drug Rezzayo met its primary endpoint in the phase 3 ReSPECT trial, showing non-inferiority to standard antimicrobial regimens in preventing ...

DUBAI, United Arab Emirates, Dec. 12, 2017 /PRNewswire/ -- Mundipharma has expanded its ophthalmology portfolio in the Middle East and Africa by agreeing a new commercial partnership with NTC -- an ...

Enrolment completed in Phase III ReSPECT study in prophylaxis of fungal infections in adult patients undergoing allogeneic blood and marrow transplant Topline results from ReSPECT study expected by ...

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 If ...

HONG KONG, May 5 (Reuters) - Drugmaker Mundipharma International Ltd，owned by the billionaire American Sackler family, has kicked off the sale of its China unit in a deal that could fetch more than $1 ...

The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its ...

German biotech CellAct has brought its cancer drug CAP7.1 through to phase 2 testing with a little over $10 million in financing—and has now claimed the reward of a $250 million partnership with ...

This exclusive agreement strengthens previous alliances with Mundipharma and its network of independent associated companies in cancer supportive care across multiple territories worldwide. Helsinn, ...